Cited by 481Immunotherapy and Immune ResponsesImmune responses and vaccinationsHIV Research and Treatment

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Heterologous prime-boost vaccination

Open access

Lu, Shan·2009·Current Opinion in Immunology

DOI 10.1016/j.coi.2009.05.016PMC PMC3743086

Open this paper in CoChat — free account Open PDF

Abstract

An effective vaccine usually requires more than one time immunization in the form of prime-boost. Traditionally the same vaccines are given multiple times as homologous boosts. New findings suggested that prime-boost can be done with different types of vaccines containing the same antigens. In many cases such heterologous prime-boost can be more immunogenic than homologous prime-boost. Heterologous prime-boost represents a new way of immunization and will stimulate better understanding on the immunological basis of vaccines.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.coi.2009.05.016

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity
Shiver, J. W., Fu, T., Chen, L., Casimiro, D. R., Davies, M.-E., Evans, R. K., Zhang, Z., Simon, A. J., Trigona, W. L., Dubey, S. A., et al. (2002) · Nature · doi:10.1038/415331a · Cited by 1,173
Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA Vaccine
Amara, R. R. (2001) · Science · doi:10.1126/science.1058915 · Cited by 1,110
The prime-boost strategy: exciting prospects for improved vaccination
Ramshaw, I. A., & Ramsay, A. J. (2000) · Immunology Today · doi:10.1016/s0167-5699(00)01612-1 · Cited by 373
Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus.
Girard, M. P., Kiény, M. P., Pinter, A., Barré‐Sinoussi, F., Nara, P. L., Kolbe, H. V. J., Kusumi, K., Chaput, A., Reinhart, T. A., & Muchmore, E. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.2.542 · Cited by 353
Protection of Macaques Against SIV Infection by Subunit Vaccines of SIV Envelope Glycoprotein gp160
Hu, S.-L., Abrams, K., Barber, G. N., Moran, P. A., Zarling, J. M., Langlois, A. J., Kuller, L., Morton, W. R., & Benveniste, R. Ė. (1992) · Science · doi:10.1126/science.1531159 · Cited by 335
Enhanced T-Cell Immunogenicity and Protective Efficacy of a Human Immunodeficiency Virus Type 1 Vaccine Regimen Consisting of Consecutive Priming with DNA and Boosting with Recombinant Fowlpox Virus
Kent, S. J., Zhao, A., Best, S. J., Chandler, J. D., Boyle, D. B., & Ramshaw, I. A. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.10180-10188.1998 · Cited by 325
Effective Induction of Simian Immunodeficiency Virus-Specific Cytotoxic T Lymphocytes in Macaques by Using a Multiepitope Gene and DNA Prime-Modified Vaccinia Virus Ankara Boost Vaccination Regimen
Hanke, T., Samuel, R. V., Blanchard, T. J., Neumann, V. C., Allen, T. M., Boyson, J. E., Sharpe, S. A., Cook, N. M., Smith, G. L., Watkins, D. I., et al. (1999) · Journal of Virology · doi:10.1128/jvi.73.9.7524-7532.1999 · Cited by 304
An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses
Harari, A., Bart, P., Stöhr, W., Tapia, G., Garcia, M., Medjitna-Rais, E., Burnet, S., Cellerai, C., Erlwein, O. W., Barber, T., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071331 · Cited by 299
Priming for and induction of anti-poliovirus neutralizing antibodies by synthetic peptides
Emini, E. A., Jameson, B. A., & Wimmer, E. (1983) · Nature · doi:10.1038/304699a0 · Cited by 237
A group specific anamnestic immune reaction against HIV-1 induced by a candidate vaccine against AIDS
Zagury, D., Bernard, J., Cheynier, R., Desportes, I., Leonard, R., Fouchard, M., Réveil, B., Ittelé, D., Lurhuma, Z., Mbayo, K., et al. (1988) · Nature · doi:10.1038/332728a0 · Cited by 185

Show all 40 references

Sorted by citations

Items 301–400 of 480

Phosphorylcholine intranasal immunization with a 13-valent pneumococcal conjugate vaccine can boost immune response against Streptococcus pneumoniae
Ohori, J., Iuchi, H., Maseda, Y., & Kurono, Y. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.10.043 · Cited by 8
Expression and immunogenicity of novel subunit enterovirus 71 VP1 antigens
Xu, J., Wang, S., Gan, W., Zhang, W., Ju, L., Huang, Z., & Lu, S. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.03.067 · Cited by 8
Self-citation
Heterologous DNA Prime/Protein Boost Immunization Targeting Nef-Tat Fusion Antigen Induces Potent T-cell Activity and in vitro Anti-SCR HIV-1 Effects
Sadeghi, L., Bolhassani, A., Mohit, E., Baesi, K., & Aghasadeghi, M. R. (2024) · Current HIV Research · doi:10.2174/011570162x297602240430142231 · Cited by 7
Multi-Antigen Elephant Endotheliotropic Herpesvirus (EEHV) mRNA Vaccine Induces Humoral and Cell-Mediated Responses in Mice
Watts, J. R., Clinton, J. L. S., Pollet, J. B. K., Peng, R., Tan, J., & Ling, P. D. (2024) · Vaccines · doi:10.3390/vaccines12121429 · Cited by 7
Challenges associated with pertussis detection, monitoring, and vaccination in adults
Regan, A. K. (2025) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2025.2516556 · Cited by 7
Reactogenicity to the mRNA-1273 Booster According to Previous mRNA COVID-19 Vaccination
Parés‐Badell, O., Zules-Oña, R., Armadans, L., Pinós, L., Borràs-Bermejo, B., Otero‐Romero, S., Rodrigo‐Pendás, J. Á., Vivet-Escalé, M., Cossio‐Gil, Y., Agustí, A., et al. (2022) · Vaccines · doi:10.3390/vaccines10081217 · Cited by 7
The protection afforded to cattle immunized with Theileria annulata infected cell line is enhanced by subunit vaccine candidate Ta SP
Saaid, A. A., Salih, D. A., Elhaj, L. M., Abdalla, M. A., Baumann, M., Obara, I., Ahmed, J. S., Clausen, P.-H., & Hussein, A. R. M. E. (2020) · Transboundary and Emerging Diseases · doi:10.1111/tbed.13374 · Cited by 7
Dodecin as carrier protein for immunizations and bioengineering applications
Bourdeaux, F., Kopp, Y., Lautenschläger, J., Gößner, I., Besir, H., Vabulas, R. M., & Grininger, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-69990-0 · Cited by 7
Oncolytic Rhabdovirus Vaccine Boosts Chimeric Anti-DEC205 Priming for Effective Cancer Immunotherapy
Tzelepis, F., Birdi, H. K., Jirovec, A., Boscardin, S. B., de Souza, C. T., Hooshyar, M., Chen, A., Sutherland, K., Parks, R. J., Werier, J. A., et al. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.10.007 · Cited by 7
Immunological Study of Combined Administration of SARS-CoV-2 DNA Vaccine and Inactivated Vaccine
Meng, Z., Ma, D., Duan, S., Zhang, J., Yue, R., Li, X., Gao, Y., Li, X., Zeng, F., Xu, X., et al. (2022) · Vaccines · doi:10.3390/vaccines10060929 · Cited by 7
Safety and Immunogenicity of a Heterologous Booster of Protein Subunit Vaccine MVC-COV1901 after Two Doses of Adenoviral Vector Vaccine AZD1222
Cheng, S., Lin, Y., Chen, C., & Cheng, C. (2022) · Vaccines · doi:10.3390/vaccines10101701 · Cited by 7
Immunogenicity and Safety of Homologous and Heterologous Prime-Boost of CoronaVac® and ChAdOx1 nCoV-19 among Hemodialysis Patients: An Observational Prospective Cohort Study
Narongkiatikhun, P., Noppakun, K., Chaiwarith, R., Winichakoon, P., Vongsanim, S., Suteeka, Y., Pongsuwan, K., Kusirisin, P., Wongsarikan, N., Fanhchaksai, K., et al. (2023) · Vaccines · doi:10.3390/vaccines11040715 · Cited by 7
Safety and immunogenicity of homologous versus heterologous booster dose with AZD1222, mRNA-1273, or MVC-COV1901 SARS-CoV-2 vaccines in adults: An observer-blinded, multi-center, phase 2 randomized trial
Estephan, L., Lin, Y., Lin, Y.-T., Chen, Y., Pan, S., Hsieh, S., Torkehagen, P. F., Weng, Y.-J., Cheng, H., Estrada, J. A. G., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.04.029 · Cited by 7
Robust and protective immune responses induced by heterologous prime‐boost vaccination with DNA‐protein dimeric RBD vaccines for COVID‐19
An, Y., Zhao, G., Duan, H., Zhang, N., Duan, M., Xu, S., Liu, X., Han, Y., Zheng, T., Li, X., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28948 · Cited by 7
Protection of mice against the highly pathogenic VVIHD-J by DNA and fowlpox recombinant vaccines, administered by electroporation and intranasal routes, correlates with serum neutralizing activity
Bissa, M., Quaglino, E., Zanotto, C., Illiano, E., Rolih, V., Pacchioni, S. M., Cavallo, F., Morghen, C. D. G., & Radaelli, A. (2016) · Antiviral Research · doi:10.1016/j.antiviral.2016.09.002 · Cited by 7
Antitumor effect of adenoviral vector prime protein boost immunity targeting the MUC1 VNTRs
Wang, Y., Liu, C., Qiu, X., Wang, P., Li, B., Lu, Z.-Z., Sun, J., Wu, H., Yu, B., Wu, J., et al. (2013) · Oncology Reports · doi:10.3892/or.2013.2950 · Cited by 6
DNA and mRNA Vaccines for Chronic Viral Infections and Cancer: Rationale, Mechanisms, and Progress
Liu, M. A. (2022) · Cancers · doi:10.3390/cancers14235874 · Cited by 6
Lung-Targeted Transgene Expression of Nanocomplexed Ad5 Enhances Immune Response in the Presence of Preexisting Immunity
Yang, Y., Wu, S., Wang, Y., Shao, F., Lv, P., Li, R., Zhao, X., Zhang, J., Zhang, X., Li, J., et al. (2023) · Engineering · doi:10.1016/j.eng.2022.12.007 · Cited by 6
Prime‐boost vaccinations using recombinant flavivirus replicon and vaccinia virus vaccines: an ELISPOT analysis
Rattanasena, P., Anraku, I., Gardner, J., Le, T. T., Wang, X. J., Khromykh, A. A., & Suhrbier, A. (2010) · Immunology and Cell Biology · doi:10.1038/icb.2010.99 · Cited by 6
A comparative approach between heterologous prime-boost vaccination strategy and DNA vaccinations for rabies.
Borhani, K., Ajorloo, M., Bamdad, T., Mozhgani, S., Ghaderi, M., & Gholami, A. R. (2015) · PubMed · Cited by 6
Strong antigen-specific T-cell immunity induced by a recombinant human TERT measles virus vaccine and amplified by a DNA/viral vector prime boost in IFNAR/CD46 mice
Pliquet, É., Ruffié, C., Escande, M. C., Thalmensi, J., Najburg, V., Combredet, C., Bestetti, T., Julithe, M., Liard, C., Huet, T., et al. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2272-3 · Cited by 6
One Group's Historical Reflections on DNA Vaccine Development
Fynan, E. F., Lu, S., & Robinson, H. L. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.066 · Cited by 6
Self-citation
Heterologous vaccination strategy for containing COVID-19 pandemicPreprint
Lin, A., Liu, J., Ma, X., Zhao, F., Yu, B., He, J., Shen, M., Huang, L., Tang, H., Jiang, E., et al. (2021) · medRxiv · doi:10.1101/2021.05.17.21257134 · Cited by 6
Different immunogens and prime-boost vaccination strategies affect the efficacy of recombinant candidate vaccines against pathogenic orthopoxviruses
Radaelli, A., Zanotto, C., Brambilla, C. I., Adami, T., Paolini, F., Venuti, A., Manuka, A., Mehmeti, I., & Morghen, C. D. G. (2024) · Virology Journal · doi:10.1186/s12985-024-02534-4 · Cited by 5
Identification and characterization of two salmon louse heme peroxidases and their potential as vaccine antigens
Gislefoss, E., Gamil, A. A. A., Øvergård, A., & Evensen, Ø. (2023) · iScience · doi:10.1016/j.isci.2023.107991 · Cited by 5
Boosting of HIV-1 Neutralizing Antibody Responses by a Distally Related Retroviral Envelope Protein
Uchtenhagen, H., Schiffner, T., Bowles, E. J., Heyndríckx, L., LaBranche, C. C., Applequist, S. E., Jansson, M., de Silva, T. I., Back, J. W., Achour, A., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1301898 · Cited by 5
OX40 agonist stimulation increases and sustains humoral and cell-mediated responses to SARS-CoV-2 protein and saRNA vaccines
Duhen, R., Beymer, M., Jensen, S. M., Abbina, S., Abraham, S., Jain, N., Thomas, A. M., Geall, A. J., Hu, H., Fox, B. A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.896310 · Cited by 5
Optimal therapeutic strategy using antigen‐containing liposomes selectively delivered to antigen‐presenting cells
Iyoda, T., Yamasaki, S., Kawamura, M., Ueda, M., Son, K., Ito, Y., Shimizu, K., & Fujii, S. (2019) · Cancer Science · doi:10.1111/cas.13934 · Cited by 5
Navigating the Quagmire: Comparison and Interpretation of COVID-19 Vaccine Phase 1/2 Clinical Trials
Giurgea, L. T., & Memoli, M. J. (2020) · Vaccines · doi:10.3390/vaccines8040746 · Cited by 5
Novel Coronavirus: A Review from Origin to Current Status of Therapeutic Strategies
Hassan, M., Zalkifal, M., Wahab, A., Afzal, S., Rafique, S., Shahid, M., Khan, M. A., Ahmed, N., Idrees, M., & Shahıd, A. A. (2021) · Critical Reviews in Eukaryotic Gene Expression · doi:10.1615/critreveukaryotgeneexpr.2021038075 · Cited by 6
Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC]
Poh, X. Y., Lee, I. R., Lim, C., Teo, J., Rao, S., Chia, P. Y., Ong, S. W. X., Lee, T. H., Kline, S., Ng, L. F. P., et al. (2022) · Trials · doi:10.1186/s13063-022-06345-2 · Cited by 6
COVID-19-Impfungen: Replizierend oder Nichtreplizierend?
Klimek, L., Chaker, A. M., Cuevas, M., & Becker, S. (2021) · Laryngo-Rhino-Otologie · doi:10.1055/a-1509-8916 · Cited by 5
Assessment of immunological markers and booster effects of Ag85B peptides, Ag85B, and BCG in blood of BCG vaccinated children: a preliminary report
Husain, A. A., Daginawala, H. F., Singh, L., & Kashyap, R. S. (2016) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2016.5.1.31 · Cited by 5
Leishmania major adenylate kinase immunization offers partial protection to a susceptible host
Zutshi, S., Kumar, S., Sarode, A. Y., Roy, S., Sarkar, A., & Saha, B. (2019) · Parasite Immunology · doi:10.1111/pim.12688 · Cited by 5
ZVex™, a dendritic-cell-tropic lentivector, primes protective antitumor T cell responses that are significantly boosted using heterologous vaccine modalities
Leleux, J. A., Albershardt, T. C., Parsons, A. J., ter Meulen, J., & Berglund, P. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.08.003 · Cited by 5
Goals and strategies in vaccine development against tuberculosis
Konjengbam, B. D., Meitei, H. N., Pandey, A., & Haobam, R. (2025) · Molecular Immunology · doi:10.1016/j.molimm.2025.04.016 · Cited by 4
RNA vaccines for cancer: revolutionizing immunization strategies
Huang, D., Zhang, J., Zeng, X., Zhang, Y., & Song, E. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.09.003 · Cited by 4
Combating respiratory diseases with mucosal vaccines
Tang, P. C. H., Ling, Z., Lee, M., King, N. J. C., & Mahalingam, S. (2026) · Journal of Virology · doi:10.1128/jvi.00146-26 · Cited by 5
Harnessing the Immune System to Fight Cancer: The Promise of Genetic Cancer Vaccines
Aurisicchio, L., & Ciliberto, G. (2011) · InTech eBooks · doi:10.5772/24410 · Cited by 4
Self-reported side effects of COVID-19 vaccines among the public
Karuppannan, M., Ming, L. C., Wahab, M. S. A., Noordin, Z. M., Yee, S., & Hermansyah, A. (2024) · Journal of Pharmaceutical Policy and Practice · doi:10.1080/20523211.2024.2308617 · Cited by 5
The fast-track development of COVID-19 vaccines
El‐Maradny, Y. A., Ramadan, A. A., Chavda, V. P., Balar, P. C., & Redwan, E. M. M. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18564-9.00027-8 · Cited by 5
Intranasal Prime–Boost with Spike Vectors Generates Antibody and T-Cell Responses at the Site of SARS-CoV-2 Infection
Metko, M. M., Tonne, J. M., Rios, A. V., Thompson, J., Mudrick, H. E., Masopust, D., Díaz, R. M., Barry, M. A., & Vile, R. G. (2024) · Vaccines · doi:10.3390/vaccines12101191 · Cited by 4
Genetic and subunit vaccines based on the stem domain of the equine influenza hemagglutinin provide homosubtypic protection against heterologous strains
Ibañez, L. I., Caldevilla, C., Rojas, Y. P., & Mattion, N. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.02.019 · Cited by 4
Exploring Prime-Boost Vaccination Regimens with Different H1N1 Swine Influenza A Virus Strains and Vaccine Platforms
Parys, A., Vandoorn, E., Chiers, K., Passvogel, K., Fuchs, W., Mettenleiter, T. C., & Reeth, K. V. (2022) · Vaccines · doi:10.3390/vaccines10111826 · Cited by 4
Transient T Cell Expansion, Activation, and Proliferation in Therapeutically Vaccinated Simian Immunodeficiency Virus-Positive Macaques Treated with N-803
Harwood, O. E., Balgeman, A. J., Weaver, A. J., Ellis-Connell, A. L., Weiler, A. M., Erickson, K. N., Matschke, L. M., Golfinos, A. E., Vezys, V., Skinner, P. J., et al. (2022) · Journal of Virology · doi:10.1128/jvi.01424-22 · Cited by 3
Mouse study of combined DNA/protein COVID-19 vaccine to boost high levels of antibody and cell mediated immune responses
He, Q., Liu, S., Liang, Z., Lu, S., Cun, W., & Mao, Q. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2152388 · Cited by 4
Self-citation
Heterologous DNA-prime/protein-boost immunization with a monomeric SARS-CoV-2 spike antigen redundantizes the trimeric receptor-binding domain structure to induce neutralizing antibodies in old mice
Pflumm, D., Seidel, A., Klein, F. A. C., Groß, R. M., Krutzke, L., Kochanek, S., Kroschel, J., Münch, J., Stifter, K., & Schirmbeck, R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1231274 · Cited by 5
How to and should we target EBV in MS?
Eckert, S. P., Jakimovski, D., Zivadinov, R., Hicar, M. D., & Weinstock‐Guttman, B. (2024) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2024.2328739 · Cited by 4
Comparison of the Efficacy of HIV-1 Nef-Tat-Gp160-p24 Polyepitope Vaccine Candidate with Nef Protein in Different Immunization Strategies
Bolhassani, A., Namazi, F., & Davoodi, S. (2021) · Current Drug Delivery · doi:10.2174/1567201818666210224101144 · Cited by 4
A field comparison of heterologous and homologous routes of administration of modified live vaccines for the control of bovine respiratory disease in recently weaned beef calves.
Erickson, N., Ellis, J., Waldner, C., Lardner, H. A., Gow, S., Campbell, J., & Berenik, A. (2020) · PubMed Central · Cited by 4
Heterologous immunization with adenovirus vectored and inactivated vaccines effectively protects against SARS-CoV-2 variants in mice and macaques
He, Q., Mao, Q., Zhang, J., Gao, F., Bai, Y., Cui, B., Liu, J., An, C., Wang, Q., Yan, X., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.949248 · Cited by 4
Editorial overview: Vaccines against challenging viral pathogens and new vaccine technology
Lu, S. (2014) · Current Opinion in Virology · doi:10.1016/j.coviro.2014.04.006 · Cited by 5
Self-citation
Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, July – November 2021
(2022) · doi:10.1101/2022.03.29.22273086 · Cited by 4
Developments in virus-like particle-based vaccines for HIV
Buonaguro, L., Tagliamonte, M., Visciano, M. L., Tornesello, M. L., & Buonaguro, L. (2014) · doi:10.2217/fmeb2013.13.61 · Cited by 4
Application of “B+1” heterologous boosting strategy for preventing infection of SARS-CoV-2 variants with resistance to broad-spectrum coronavirus vaccines
Liu, Z., Lu, L., & Jiang, S. (2023) · Emerging Microbes & Infections · doi:10.1080/22221751.2023.2192817 · Cited by 4
Immunization with virus-like vesicle-based COVID-19 vaccine induces robust systemic and mucosal immunity
Yang, L., Yarovinsky, T. O., Pham, K., Xi, Y., Lu, P., Iwasaki, A., Rose, J. K., & Liu, C. (2025) · npj Vaccines · doi:10.1038/s41541-025-01260-4 · Cited by 3
Pre-existing humoral immunity and CD4+ T cell response correlate with cross-reactivity against SARS-CoV-2 Omicron subvariants after heterologous prime-boost vaccination
Shen, C., Fu, Y.-C., Ho, T., Chen, P., Lee, N., Tsai, B., Tsai, P.-J., Ko, W., Liu, H., Cheng, C., et al. (2023) · Clinical Immunology · doi:10.1016/j.clim.2023.109342 · Cited by 3
Heterologous prime–boost Zika virus vaccination induces comprehensive humoral and cellular immunity in mouse models
Lorenzo, G. D., Tandavanitj, R., Preciado‐Llanes, L., Sanchez-Velazquez, R., Rocha, R. P., Kim, Y. C., Reyes‐Sandoval, A., & Patel, A. H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1578427 · Cited by 3
Induction of an Antibody Response against Plasmodium falciparum F2RIIEBA by Heterologous Prime-boost Immunisation.
Suppıan, R., & Norazmi, M. N. (2013) · Europe PMC (PubMed Central) · Cited by 3
Chimeric Myostatin — Tetanic Toxin Epitopes and Heterologous Prime-boost Immunization Improve Immune Response Stimulating Muscle Growth in Mice
Ramírez-Andoney, V., Gayosso-Vázquez, A., Ríos, J. P. P., Buchelli, J. E. V., & Morales, R. A. A. (2019) · Biotechnology and Bioprocess Engineering · doi:10.1007/s12257-019-0092-8 · Cited by 3
Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials
Fischinger, S., Cizmeci, D., Deng, D., Grant, S., Frahm, N., McElrath, M. J., Fuchs, J. D., Bart, P., Pantaleo, G., Keefer, M. C., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1010016 · Cited by 3
Evaluation of immunogenicity-induced DNA vaccines against different SARS-CoV-2 variants
Kim, S. E., Park, S., Park, W.-J., Kim, G., Kim, S. Y., Won, H., Hwang, Y.-H., Lim, H., Kim, H. G., Kim, Y.-J., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0295594 · Cited by 3
Heterologous Booster Immunization Based on Inactivated SARS-CoV-2 Vaccine Enhances Humoral Immunity and Promotes BCR Repertoire Development
Li, X., Zeng, F., Yue, R., Ma, D., Meng, Z., Li, Q., Zhang, Z., Zhang, H., Liao, Y., Liao, Y., et al. (2024) · Vaccines · doi:10.3390/vaccines12020120 · Cited by 3
Immunization with centrin-Deficient Leishmania braziliensis Does Not Protect against Homologous Challenge
Avendaño-Rangel, F., Duarte, G. A., Borba, P. B., Moitinho, V. S., Ávila, L. T., da Silva, L. O., Viana, S. M., Sharma, R., Gannavaram, S., Nakhasi, H. L., et al. (2024) · Vaccines · doi:10.3390/vaccines12030310 · Cited by 3
Nucleic Acid Vaccines
Devi, W. R., Kammar, S. S., Logesh, S., Dsouza, G. L., Mohan, T. C., & Rajulu, C. (2022) · Journal of Preventive Diagnostic and Treatment Strategies in Medicine · doi:10.4103/jpdtsm.jpdtsm_85_22 · Cited by 3
HeterologousPrime-Boost immunizationwithAdenoviral vector and recombinant subunit vaccines strategies against dengue virus type2
Shoushtari, M. M., Salehi-Vaziri, ‪., Kadkhodazadeh, M., Teimoori, A., Arashkia, A., Roohvand, F., Teimoori‐Toolabi, L., Pouriayevali, M. H., & Azadmanesh, K. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114032 · Cited by 3
Homologous and Heterologous Prime-Boost Vaccination: Impact on Clinical Severity of SARS-CoV-2 Omicron Infection among Hospitalized COVID-19 Patients in Belgium
Meurisse, M., Catteau, L., van Loenhout, J. A. F., Braeye, T., Mot, L. D., Serrien, B., Blot, K. Y., Cauët, É., Oyen, H. J. V., Cuypers, L., et al. (2023) · Vaccines · doi:10.3390/vaccines11020378 · Cited by 3
Enhanced humoral and cellular immune responses to PRRS virus GP5 glycoprotein by DNA prime-adenovirus boost vaccination in mice
Yu, M., Qiu, Y., Chen, J., & Jiang, W. (2016) · Virus Genes · doi:10.1007/s11262-016-1293-2 · Cited by 3
Therapeutic Use of Human Papillomavirus Vaccines in Cervical Lesions
Castro-Eguiluz, D., Barquet-Muñoz, S. A., Arteaga-Gómez, A. C., Hernández, R. A. S., Rodríguez-Trejo, A., Gallardo‐Rincón, D., Serrano-Olvera, J. A., & Aranda-Flores, C. E. (2020) · Revista de investigaci�n Cl�nica · doi:10.24875/ric.20000059 · Cited by 3
Use of Biologics in the Prevention of Infectious Diseases
Pusterla, N., Plummer, P. J., Cortese, V. S., Wilson, W. D., Kreuder, A. J., Duhamel, G. E., Ellis, J. A., Fulton, R. W., Uzal, F. A., Taylor, J. D., et al. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-55445-9.00048-3 · Cited by 2
A prime-boost combination of a three-protein cocktail and multiepitopic MVA as a vaccine against Babesia bigemina elicits neutralizing antibodies and a Th1 cellular immune response in mice
Montenegro, V. N., Jaramillo-Ortiz, J. M., Paoletta, M. S., Gravisaco, M. J., Zajac, M. P. D. M., Garanzini, D., Valenzano, M. N., Calamante, G., & Wilkowsky, S. E. (2022) · Ticks and Tick-borne Diseases · doi:10.1016/j.ttbdis.2022.101991 · Cited by 2
Systematic Review of the SARS-CoV-2 Viral Vector Vaccine AstraZeneca (Azd1222)
Zahid, R., & Riaz, S. (2022) · BioScientific Review · doi:10.32350/bsr.42.i · Cited by 2
SARS-CoV-2 specific antibody response after an mRNA vaccine as the third dose: Homologous versus heterologous boost
Lijeskić, O., Bauman, N., Marković, M., Srbljanović, J., Bobić, B., Zlatković, Đ., & Štajner, T. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.01.085 · Cited by 2
Decade-Long Sustained Cellular Immunity Induced by Sequential and Repeated Vaccination with Four Heterologous HIV Vaccines in Rhesus Macaques
He, X., Chen, D., Ma, Q., Hao, Y., Li, H., Zhang, X., Cao, Y., & Feng, X. (2025) · Vaccines · doi:10.3390/vaccines13040338 · Cited by 2
Immunogenicity and Safety of Heterologous Versus Homologous Prime-Boost Regimens With BBIBP-CorV and Ad26.COV2.S COVID-19 Vaccines: A Multicentric, Randomized, Observer-Blinded Non-inferiority Trial in Madagascar and Mozambique
Ramgi, P., Siribié, M., Rakotozandrindrainy, N., Bule, O., Shrivastava, H., Chambule, L., Park, E. L., Fernando, C. V., Boque, J., Macuiana, R., et al. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf130 · Cited by 2
Choosing between Homologous or Heterologous COVID-19 Vaccination Regimens: A Cross-Sectional Study among the General Population in Italy
Clari, M., Godono, A., Albanesi, B., Casabona, E., Comoretto, R. I., Mansour, I., Conti, A., Dimonte, V., & Ciocan, C. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19052944 · Cited by 2
DNA Vaccines: Experiences in the Swine Model
Accensi, F., Rodrı́guez, F., & Monteagudo, P. L. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-3008-1_4 · Cited by 2
Microparticles and Nanoparticles for Cancer-Targeting Vaccines
Morris, A. S., Wongrakpanich, A., Geary, S. M., & Salem, A. K. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-39981-4.00009-9 · Cited by 2
КРИТЕРИИ ДЛЯ ИНДУКЦИИ НЕЙТРАЛИЗУЮЩИХ АНТИТЕЛ ШИРОКОГО СПЕКТРА ДЕЙСТВИЯ ПРОТИВ ВИЧ-1 С ПОМОЩЬЮ ВАКЦИНАЦИИ, "Молекулярная биология"
Vzorov, A. N., & Lv, U. (2017) · Molecular Biology · doi:10.7868/s0026898417060076 · Cited by 2
DURATION OF IMMUNE RESPONSE INDUCED BY THE VACCINE BASED ON RECOMBINANT Ag85, TB10 AND FliC PROTEINS
Yeremeev, V., Dukhovlinov, I. V., Орлов, А. И., Сергеевна, Ш. Г., Fedorova, E. A., Balazovsky, M. B., & Gergert, V. Y. (2018) · Medical Immunology (Russia) · doi:10.15789/1563-0625-2018-2-271-276 · Cited by 2
Immune Response of a Heterologous mRNA-1273 Second-Dose Immunization after a First Dose of ChadOx1 against SARS-CoV-2: A Cross-Sectional Study
Albanesi, B., Godono, A., Comoretto, R. I., Casabona, E., Curoso, G., Leone, M. V., Milanesio, N., Mirra, I., Montrucchio, G., Pittaluga, F., et al. (2022) · Vaccines · doi:10.3390/vaccines10081241 · Cited by 2
Perception and Acceptance of Using Different Generic Types of COVID-19 Vaccine, the “Mix-and-Match” Strategy, in Saudi Arabia: Cross-Sectional Web-Based Survey
Alqurashi, A., Sindy, E. A., Dosh, H. Y., Khayat, S. Z., Alqarna, L. M., Sodagar, W. M., Samannodi, M. S., Alwafi, H. H., Salawati, E. M., Almatrafi, M. A., et al. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph192113889 · Cited by 2
The Correlated Beta Dose Optimisation Approach: Optimal Vaccine Dosing Using Mathematical Modelling and Adaptive Trial Design
Benest, J., Rhodes, S., Evans, T. G., & White, R. G. (2022) · Vaccines · doi:10.3390/vaccines10111838 · Cited by 2
Heterologous prime-boost vaccine using antigen-loaded microparticles and adenovirus (encoding antigen) enhances cellular immune responses and antitumor activity
Ellis, A. A., Geary, S. M., & Salem, A. K. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.122932 · Cited by 2
Evaluation of Immune Response to Mucosal Immunization with an Oral Probiotic-Based Vaccine in Mice: Potential for Prime-Boost Immunization against SARS-CoV-2
Leontieva, G., Gupalova, T. V., Desheva, Y. A., Kramskaya, T. A., Bormotova, E., Koroleva, I. V., Kopteva, O. S., & Suvorov, A. N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010215 · Cited by 2
Enhanced effectiveness in preventing Nocardia seriolae infection utilizing heterologous prime-boost approach in orange-spotted grouper Epinephelus coioides
Nguyen, P. T. D., Giovanni, A., Maekawa, S., Wang, P., & Chen, S. (2024) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2024.109663 · Cited by 2
Human immunodeficiency virus vaccines
Girard, M. P., & Koff, W. C. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-0090-5.00054-9 · Cited by 2
An investigation into the Use of Lumpy Skin Disease Virus as a Vaccine Vector for a Potential HIV-1 vaccine
Shen, Y.-J. (2010) · Open University of Cape Town (University of Cape Town) · Cited by 2
Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, January – September 2021
(2021) · doi:10.1101/2021.11.12.21266222 · Cited by 1
Homologous and Heterologous Covid-19 Booster Vaccinations Against SARS-CoV-2 Infection in the Elderly
Acer, Ö., Bahçe, Y. G., & Özüdoğru, O. (2024) · Current Microbiology · doi:10.1007/s00284-024-03689-7 · Cited by 1
Circulating T cell subpopulations in dairy calves infected with Bovine viral diarrhea virus 2 and Bovine herpes virus 1 following modified-live virus booster vaccination: Effects of the administration route and trace mineral supplementation
Hoyos‐Jaramillo, A., Palomares, R. A., Bittar, J. H. J., Hurley, D. J., Rodríguez, A., Altamiranda, E. A. G., Kirks, S., Gutierrez, A., Wall, S., Miller, K., et al. (2025) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2024.110871 · Cited by 1
Tailoring mRNA lipid nanoparticles for antifungal vaccines
Li, Y., Meagher, R. B., & Lin, X. (2025) · PLoS Pathogens · doi:10.1371/journal.ppat.1013091 · Cited by 1
Distinct humoral responses induced by heterologous versus homologous prime–boost immunization strategies in early life
Pajoohian, P. F., Pind, A. A. A., Estupiñan, J. L. M., Christensen, D., Pedersen, G. K., Olafsdottir, T. A., Jónsdóttir, I., & Bjarnarson, S. P. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1563345 · Cited by 1
Current Status and Challenges of Vaccine Development for Seasonal Human Coronaviruses
Zhang, B., Liu, Y., Chen, T., Lai, J., Liu, S., Liu, X., Zhu, Y., Rao, H., Peng, H., & Ma, X. (2025) · Vaccines · doi:10.3390/vaccines13111168 · Cited by 2
Immunogenicity and efficacy of homologous and heterologous NDV and MVA SARS-CoV-2 vaccines in mice and hamsters
Pérez, P., Jiang, K., González‐Domínguez, I., Rodríguez-Martín, D., Abdeljawad, A., Čupić, A., Slamanig, S., Flores, S., Noriega, M. A., Sánchez‐Cordón, P. J., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01299-3 · Cited by 1
Therapeutic hepatitis B vaccine employing DNA prime – MVA boost scheme requires additional priming with recombinant HBsAg to elicit an adequate antibody response
Kerth, H. A., Kächele, M., Müller, N., Singh, S., Tulessin, M., Sacherl, J., Öz, E. A., Su, J., Bester, R., Miko, S., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1771887 · Cited by 1
Assessment of Mycobacterium tuberculosis dodecin scaffold as a multimerization platform on the immunogenicity of HPV L2 antigens
Kaplan, E., Mariz, F. C., Zhao, X., Neßling, M., Veitl, L., Zhang, Y., Weyd, H., & Müller, M. (2026) · Scientific Reports · doi:10.1038/s41598-026-42678-7 · Cited by 1
Protein Priming Followed by a Replication-Competent VSV-GP Vector Boost Induces Sustained Immune Control in Therapeutic Hepatitis B Vaccination
Su, J., Kosinska, A. D., Miko, S., Öz, E. A., von Laer, D., Kimpel, J., & Protzer, U. (2026) · Vaccines · doi:10.3390/vaccines14030266 · Cited by 1
Homologous MVA and heterologous DREP/MVA vaccine regimens induce robust and durable immune responses against SARS-CoV-2
Pérez, P., Esteso, G., Noriega, M. A., Vidakovics, L. P., Liljeström, P., McInerney, G. M., Estéban, M., & García-Arriaza, J. (2026) · Scientific Reports · doi:10.1038/s41598-026-46699-0 · Cited by 1
Modeling the Dependence of Immunodominance on T Cell Dynamics in Prime-Boost Vaccines
Arias, C. F., Herrero, M. A., Bertocchini, F., Acosta, F. J., & Fernández-Arias, C. (2020) · Mathematics · doi:10.3390/math9010028 · Cited by 1

Authors: Lu, S.
Affiliations: Jiangsu Province Hospital (CN)
Corresponding author: Lu, Shan
ORCID: Lu, Shan
Venue: Current Opinion in Immunology
Publisher: Elsevier BV
Published: 2009-06
Volume: 21
Issue: 3
Pages: 346-351
ISSN: 0952-7915 (ISSN-L)
DOI: 10.1016/j.coi.2009.05.016
PMC: PMC3743086
OpenAlex: W1979742563
Cited by: 481
References: 40
Citations by year: 2026: 15 · 2025: 25 · 2024: 21 · 2023: 32 · 2022: 66 · 2021: 53 · 2020: 41 · 2019: 28 · 2018: 17 · 2017: 27 · 2016: 13 · 2015: 18 · 2014: 21 · 2013: 34 · 2012: 18
FWCI: 1.81
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
doi.org/10.15223/policy-017 (stm-asf)
doi.org/10.15223/policy-037 (stm-asf)
doi.org/10.15223/policy-012 (stm-asf)
doi.org/10.15223/policy-029 (stm-asf)
doi.org/10.15223/policy-004 (stm-asf)
Locations: Current Opinion in Immunology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health
National Institute of Allergy and Infectious Diseases (P01AI082274, R01AI065250, R01 AI06250, U19AI082676)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
Keywords: heterologous prime-boost, prime-boost vaccination, vaccine immunogenicity, vaccine adjuvants
MeSH terms: Animals, Humans, Immunization, Secondary, Neoplasms, Research, Research Design, Vaccination, HIV Infections, AIDS Vaccines, Cancer Vaccines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Heterologous prime-boost vaccination

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks